Passion & Purpose in Women’s Oncology

Company Overview

Founded in late 2014 by David Portman, MD, a leading clinical researcher and expert in women’s health, menopause, and selective estrogen receptor modulators, Sermonix Pharmaceuticals is a privately held biotechnology company focused on the development and commercialization of female-specific oncology products.

The ELAINE Study

The ELAINE Study is an open-label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor 2-negative (HER2-) breast cancer with an acquired estrogen receptor 1 (ESR1) mutation and who have disease progression on an aromatase inhibitor (Al) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor*.

The primary objective is to evaluate the progression-free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation.

Lasofoxifene

Sermonix is investigating lasofoxifene, which has been extensively studied, for breast and ovarian cancer treatments.
We are investigating whether lasofoxifene may benefit certain women with metastatic breast cancer by delaying disease progression while offering a differentiated safety profile. See if you prequalify for The ELAINE Study.
Use the ZIP Code locator to find contact information for the study location nearest you.

Find Study near you

News

Get the latest updates about clinical trial results and company news.

View All

Medical Meetings

View and download poster presentations from oncology meetings.

View All